ALDH1 is an independent prognostic factor for patients with stages II-III rectal cancer after receiving radiochemotherapy.
ALDH1 is an independent prognostic factor for patients with stages II-III rectal cancer after receiving radiochemotherapy.
复制标题
DOI：
10.1038/bjc.2013.767
复制
发表时间：
2014-01-21
影响因子：
8.8
通讯作者：
Wang, J.
中科院分区：
文献类型：
--
作者：
Deng, Y.;Zhou, J.;Fang, L.;Cai, Y.;Ke, J.;Xie, X.;Huang, Y.;Huang, M.;Wang, J.
约五分之一的局部晚期直肠癌（RC）患者在新辅助治疗后复发或远处转移。我们研究了新辅助治疗后癌症干细胞标志物的变化以及这些标志物与复发的关系。治疗前活检和术后标本取自64例局部晚期直肠腺癌患者，这些患者在取样之间接受了术前放化疗（RCT）。对样本进行CD 44、LGR 5、ALDH 1和CD 166的免疫化学检测;评分分为高或低。中位随访期为36个月。CD 44、LGR 5、ALDH和CD 166的高表达率在RCT前分别为38%、5%、48%和10%，在RCT后分别为86%、33%、71%和52%。RCT后CD 44（P=0.001）、LGR 5（P=0.049）和CD 166（P=0.003）显著上调。低ALDH组随访期间未见复发，而高ALDH组有40%复发。在多变量考克斯分析中，术后ALDH 1独立预测接受RCT的RC患者的不良预后（P=0.0095）。术前RCT上调RC患者干细胞标志物的表达治疗后ALDH 1高表达预示这些患者在新辅助治疗后预后不良。
About one in five patients with locally advanced rectal cancer (RC) suffers recurrence or distant metastasis after neoadjuvant therapy. We investigated how cancer stem cell markers change after neoadjuvant therapy and how these markers relate to recurrence. Pretreatment biopsies and postoperative specimens were taken from 64 patients with locally advanced rectal adenocarcinoma who received preoperative radiochemotherapy (RCT) between sampling. Samples were tested immunohistochemically for CD44, LGR5, ALDH1 and CD166; scores were dichotomised as high or low. The median follow-up period was 36 months. High expression of CD44, LGR5, ALDH and CD166 was found in 38%, 5%, 48% and 10%, respectively, before RCT and 86%, 33%, 71% and 52%, respectively, after RCT. CD44 (P=0.001), LGR5 (P=0.049) and CD166 (P=0.003) were significantly upregulated after RCT. Whereas no recurrence was seen during the follow-up in the low ALDH group, 40% of the high ALDH group suffered recurrence. In multivariate COX analysis, postoperative ALDH1 independently predicted poor prognosis in patients with RC who received RCT (P=0.0095). Preoperative RCT upregulates expression of stem cell markers in patients with RC. High post-treatment ALDH1 expression predicts poor prognosis for these patients after neoadjuvant therapy.
登录
查看更多内容
影响因子：
8.8
作者：
通讯作者：
--
影响因子：
11.2
作者：
Huang EH;Hynes MJ;Zhang T;Ginestier C;Dontu G;Appelman H;Fields JZ;Wicha MS;Boman BM
通讯作者：
Boman BM
影响因子：
3.3
作者：
Avoranta, S. Tuulia;Korkeila, Eija A.;Sundstrom, Jari T. T.
通讯作者：
Sundstrom, Jari T. T.
影响因子：
64.8
作者：
O'Brien, Catherine A.;Pollett, Aaron;Dick, John E.
通讯作者：
Dick, John E.
影响因子：
158.5
作者：
Sauer, R;Becker, H;Raab, R
通讯作者：
Raab, R